

Synthesis of Benzo[5',6']cyclohepta[4,5]pyrrolo[2,3-*b*]pyridin-12-one

Abderrahim Mouaddib,^{b,c} Benoît Joseph,^a Aissa Hasnaoui,^c and Jean-Yves Mérou^{a*}

^aInstitut de Chimie Organique et Analytique associé au CNRS, Université d'Orléans, BP 6759, 45067 Orléans Cedex 2, France

^bFaculté des Sciences et Techniques, Béni Mellal, Université Cady Ayyad, Maroc


^c Faculté des Sciences Semlalia, Marrakech, Université Cadi Ayyad, Maroc

Received 23 April 1999; accepted 8 June 1999

Abstract: The synthesis of a 7-azaindole derivative **8** with potential antitumoral activity is described starting from pyrrolo[2,3-*b*]pyridine; regioselective lithiation/methylation of alkyl 7-azaindole-3-carboxylates **4** afforded the 2-methyl derivatives **5**. Demethylation of ester **6a** using BBr_3 afforded the acid **7**, which is cyclised into the tetracyclic derivative **8**. © 1999 Published by Elsevier Science Ltd. All rights reserved.

Keyword: indole, lithiation, cyclisation, aza compounds


We have recently developed the synthesis of new tetracyclic indolic structures such as **I**,^{1,2} **II**,³ **III**⁴ which have been used as synthons for the synthesis of potential antitumoral derivatives. The promising activity of such derivatives led us to investigate the pyrrolo[2,3-*b*]pyridine (7-azaindole) nucleus in order to synthesise the analogue **8** of compound **I**. 7-azaindolic analogues of natural products such as vincamine⁵ or ellipticine⁶ have already been reported.



The reactivity of pyrrolo[2,3-*b*]pyridine moiety has been poorly investigated⁷⁻¹¹ compared to that of indole, despite the biological potential of 7-azaindoles: NADH models,¹² mimics of adenosine base¹³ and dopaminergic ligands¹⁴ illustrated the interest of the 7-azaindole structure. The lower reactivity of carbon C3 towards electrophilic substitution^{15,16} in 7-azaindole, precluded an electrophilic ring closure on this carbon atom for generating the cyclohepta ring such as in compound **8**. Thus, we preferred for preparing **8**, an approach based on the cyclohepta ring closure of the 2-substituted-7-azaindole-3-carboxylic acid **7** where the $\text{C}_3\text{-CO}$ bond is already present.

Thus, compound **7** was prepared from the key intermediate **5**, issued from the 3-formyl-7-azaindole **1**. Compound **1** was prepared from 7-azaindole by treating it with hexamethylenetetramine followed by acetic acid.¹⁵ Benzenesulfonyl chloride was added at 0 °C to the sodium salt of **1** in THF to give **2** in good yield (92%). Esters **4** can be obtained by a tedious procedure *via* the oxime/nitrile route¹⁶ described for the unsubstituted aldehyde **1**. We preferred a straightforward access to the acid **3** by a careful controlled oxidation of **2** with sodium chlorite (95% yield). It was then transformed into the methyl, ethyl or benzyl esters **4a-c** by esterification with the corresponding alcohol in acidic medium or with EDCI/DMAP. Corey oxidation ($\text{MnO}_2/\text{NaCN}/\text{EtOH}$) of **2** into **4b** did not work despite the reported oxidation of 3-formyl-1-substituted 7-azaindole derivatives.⁹ Introduction at the position-2 of **4a** or **4b** of a methyl group by lithiation (LDA/THF/-78 °C then CH_3I) afforded the pivotal intermediate **5a** or **5b** in 77% and 71% yield, respectively. Compounds **5a,b** have a high synthetic potential as referred to the indole analogues.^{17,18} A second regioselective lithiation of compounds **5a,b** was performed on the methyl group (LDA/THF/-78 °C, then benzyl bromide) to give the alkylated derivatives **6a,b**.

*Fax: 33 2 38 41 72 8; e-mail: jean-yves.merour@univ-orleans.fr



a) $\text{NaH}/\text{C}_6\text{H}_5\text{SO}_2\text{Cl}/\text{THF}/0^\circ\text{C}$, 92%; b) $\text{NaClO}_2/\text{NH}_2\text{SO}_3\text{H}/\text{Dioxane}/\text{H}_2\text{O}/\text{rt}/0.5\text{ h}$, 95%; c) ROH/HCl **4a** 91%; **4b** 94%; $\text{BnOH}/\text{EDCI}/\text{DMAP}$ **4c** 98%; d) $\text{LDA}/\text{THF}/-78^\circ\text{C}/\text{CH}_3$ **5a** 77%, **5b** 71%; e) $\text{LDA}/\text{THF}/-78^\circ\text{C}/\text{BnBr}$ **6a** 79%, **6b** 74%; f) $\text{BBR}_3/\text{CH}_2\text{Cl}_2/\text{rt}$, 86%; g) $(\text{CF}_3\text{CO})_2\text{O}/\text{BF}_3, \text{Et}_2\text{O}/\text{C}_2\text{H}_4\text{Cl}_2/\text{rt}/24\text{h}$, 62%.

The hydrolysis of the ester group of **6a,b** was not as easy as expected. All attempts, in basic media ($\text{LiOH}/\text{MeOH}/\text{H}_2\text{O}$ or K_2CO_3) were unsuccessful due to the weak electrophilic character of the carbonyl group. Nevertheless the use of boron tribromide, at room temperature, with the methyl ester **6a** cleanly afforded the desired acid **7** in 86% yield. Cyclisation of the acid with trifluoroacetic anhydride in the presence of $\text{BF}_3/\text{Et}_2\text{O}$, at room temperature, in 1,2-dichloroethane gave **8** in 62% yield; the use of PPSE in 1,2-dichloroethane at reflux gave degradation products.

This new azaindolic tricyclic derivative **8** can be used as a scaffold and will help to design potential anticancer candidates.

References and notes

- Joseph, B.; Cornec, O.; M  rour, J.-Y.; Solans, X.; Font-Bardia, M. *J. Heterocycl. Chem.* **1997**, *34*, 525-531.
- Joseph, B.; Chapellier, V.; M  rour, J.-Y.; L  once, S. *Heterocycles* **1998**, *48*, 1423-1430.
- Joseph, B.; Cornec, O.; M  rour, J.-Y. *Tetrahedron* **1998**, *54*, 7765-7776.
- Joseph, B.; Alagille, D.; Rousseau, C.; M  rour, J.-Y. *Tetrahedron* **1999**, *55*, 4341-4352.
- Ur  gdi, L.; Barta-Szalai, G.; Kisfaludy, L.; Domany, G.; Csehi, A. *Heterocycles* **1994**, *37*, 1807-1817.
- Dormoy, J. R.; Heymes, A. *Tetrahedron* **1993**, *49*, 2885-2914.
- Desarbre, E.; Coudret, S.; Meheust, C.; M  rour, J.-Y. *Tetrahedron* **1997**, *53*, 3637-3648.
- Curtis, N. L.; Kulagowski, J. J.; Leeson, P. D.; Ridgill, M. P.; Emms, F.; Freedman, S. B.; Patel, S. *Bioorg. Med. Chem. Lett.* **1999**, *9*, 585-588.
- Kato, M.; Ito K.; Nishino, S.; Yamakuni, H.; Takasugi, H. *Chem. Pharm. Bull.* **1995**, *43*, 1351-1357.
- Kelly, T. A.; McNeil, D.W.; Rose, J. M.; David, E.; Shih, C.-K.; Grob, P. M. *J. Med. Chem.* **1997**, *40*, 2430-2433.
- Lorenz, R.R.; Tullar, B.F.; Koelsch, C.F.; Archer, S. *J. Org. Chem.* **1965**, *30*, 2531-2533. Estel, L.; Marsais, F.; Gu  quiner, G. *J. Org. Chem.* **1988**, *53*, 2740-2744.
- Levacher, V.; Benoit, R.; Duflos, J.; Dupas, G.; Bourguignon, J.; Qu  quiner, G. *Tetrahedron* **1991**, *47*, 429-440.
- Kulagowski, J.J.; Broughton, H.B.; Curtis, N.R.; Mawer, I.M.; Ridgill, M.P.; Baker, R.; Emms, F.; Freedman, S.B.; Marwood, R.; Patel, S.; Patel, S.; Ragan, C.I.; Leeson, P.D. *J. Med. Chem.* **1996**, *39*, 1941-1942.
- Seela, F.; Gumbiowski, R. *Helv. Chim. Acta* **1991**, *74*, 1048-1058.
- Robison, M.; Robison, B. L. *J. Amer. Chem. Soc.* **1955**, *77*, 457-460.
- Robison, M.; Robison, B. L. *J. Amer. Chem. Soc.* **1956**, *78*, 1247-1251.
- Mohanakrishnan, A. K.; Srinivasan, P. C. *J. Org. Chem.* **1995**, *60*, 1939-1946 and references cited therein.
- Macor, J. E.; Ryan, K.; Newman, M. E. *J. Org. Chem.* **1989**, *54*, 4785-4795.
- For **8**: mp 172°C (hexane/ CH_2Cl_2); $^1\text{H-NMR}$ (250 MHz, CDCl_3): δ 3.26 (t, 2H, $J = 6.2$ Hz, CH_2), 3.76 (t, 2H, $J = 6.2$ Hz, CH_2), 7.26-7.63 (m, 7H, H_{Ar}), 7.81 (dd, 1H, $J = 1.3, 7.6$ Hz, H_{Ar}), 8.21 (d, 2H, $J = 7.6$ Hz, H_{Ar}), 8.43 (dd, 1H, $J = 1.7, 4.7$ Hz, H_{Ar}), 8.80 (dd, 1H, $J = 1.7, 7.8$ Hz, H_{Ar}); $^{13}\text{C-NMR}$ (62.9 MHz, CDCl_3): δ 29.4 (CH_2), 33.5 (CH_2), 118.3 (C), 120.7 (CH), 120.9 (C), 127.5 (CH), 128.2 (2 CH), 129.0 (CH), 129.3 (3 CH), 131.7 (CH), 132.4 (CH), 134.6 (CH), 138.2 (C), 138.9 (C), 140.0 (C), 145.3 (CH), 148.1 (C), 149.8 (C), 190.2 (CO); MS (ionspray): m/z 389 ($\text{M}^+ + 1$).